Travis J. Jerde

Travis J. Jerde

Auto-generated profile, based on publicly available information

Travis J. Jerde

Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
NSNagarathinam Selvaraj
Nagarathinam Selvaraj
JBJustin A Budka
Justin A Budka
MFMary W Ferris
Mary W Ferris
TJTravis J Jerde
Travis J Jerde
TNTaylor Nicholas
Taylor Nicholas
The RAS/ERK and PI3K/AKT pathways induce oncogenic gene expression programs and are commonly activated together in cancer cells. Often, RAS/ERK signaling is activated by mutation of the RAS or RAF oncogenes, and PI3K/AKT is activated by loss of the tumor suppressor PTEN. In prostate cancer, PTEN deletions are common, but, unlike other carcinomas, RAS and RAF mutations are rare. We have previously shown that over-expression of “oncogenic” ETS transcription factors, which occurs in about one-half of prostate tumors due to chromosome rearrangement, can bypass the need for RAS/ERK signaling in the activation of a cell migration gene expression program. In this study we test the role of RAS/ERK and PI3K/AKT signaling in the function of oncogenic ETS proteins.

13 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DMDavid W. McIlwain
David W. McIlwain
MFMelissa L. Fishel
Melissa L. Fishel
ABAlexander Boos
Alexander Boos
MKMark R. Kelley
Mark R. Kelley
TJTravis J. Jerde
Travis J. Jerde
APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells

12 May 2017 in The Prostate
Verified
Journal Article
Closed access
PDF file
DCDarrelle L. Colinot
Darrelle L. Colinot
TGTamila Garbuz
Tamila Garbuz
MBMaarten C. Bosland
Maarten C. Bosland
LWLiang Wang
Liang Wang
SRSusan E. Rice
Susan E. Rice
TJTravis J. Jerde
Travis J. Jerde

15 June 2015 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
LWLiang Wang
Liang Wang
MZMarloes Zoetemelk
Marloes Zoetemelk
BCBrahmananda R. Chitteti
Brahmananda R. Chitteti
TRTimothy L. Ratliff
Timothy L. Ratliff
JMJason D. Myers
Jason D. Myers
TJTravis J. Jerde
Travis J. Jerde
Prostatic inflammation is a nearly ubiquitous pathological feature observed in specimens from benign prostate hyperplasia and prostate cancer patients. The microenvironment of the inflamed prostate is highly reactive, and epithelial hyperplasia is a hallmark feature of inflamed prostates. How inflammation orchestrates epithelial proliferation as part of its repair and recovery action is not well understood. Here, we report that a novel epithelial progenitor cell population is induced to expand during inflammation. We used sphere culture assays, immunofluorescence, and flow cytometry to show that this population is increased in bacterially induced inflamed mouse prostates relative to naïve control prostates. We confirmed from previous reports that this population exclusively possesses the ability to regrow entire prostatic structures from single cell culture using renal grafts. In addition, putative progenitor cells harvested from inflamed animals have greater aggregation capacity than those isolated from naïve control prostates. Expansion of this critical cell population requires IL-1 signaling, as IL-1 receptor 1-null mice exhibit inflammation similar to wild-type inflamed animals but exhibit significantly reduced progenitor cell proliferation and hyperplasia. These data demonstrate that inflammation promotes hyperplasia in the mouse prostatic epithelium by inducing the expansion of a selected epithelial progenitor cell population in an IL-1 receptor-dependent manner. These findings may have significant impact on our understanding of how inflammation promotes proliferative diseases such as benign prostatic hyperplasia and prostate cancer, both of which depend on expansion of cells that exhibit a progenitor-like nature.

27 July 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
BSBrady G. Strittmatter
Brady G. Strittmatter
TJTravis J. Jerde
Travis J. Jerde
TNTaylor Nicholas
Taylor Nicholas
The TMPRSS2/ERG gene rearrangement occurs in 50% of prostate tumors and results in expression of the transcription factor ERG, which is normally silent in prostate cells. ERG expression promotes prostate tumor formation and luminal epithelial cell fates when combined with PI3K/AKT pathway activation, however the mechanism of synergy is not known. In contrast to luminal fates, expression of ERG alone in immortalized normal prostate epithelial cells promotes cell migration and epithelial to mesenchymal transition (EMT). Migration requires ERG serine 96 phosphorylation via endogenous Ras/ERK signaling. We found that a phosphomimetic mutant, S96E ERG, drove tumor formation and clonogenic survival without activated AKT. S96 was only phosphorylated on nuclear ERG, and differential recruitment of ERK to a subset of ERG-bound chromatin associated with ERG-activated, but not ERG-repressed genes. S96E did not alter ERG genomic binding, but caused a loss of ERG-mediated repression, EZH2 binding and H3K27 methylation. In contrast, AKT activation altered the ERG cistrome and promoted expression of luminal cell fate genes. These data suggest that, depending on AKT status, ERG can promote either luminal or EMT transcription programs, but ERG can promote tumorigenesis independent of these cell fates and tumorigenesis requires only the transcriptional activation function.

1 December 2014 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
AHAlana M. Hahn
Alana M. Hahn
JMJason D. Myers
Jason D. Myers
EMEliza K. McFarland
Eliza K. McFarland
SLSanghee Lee
Sanghee Lee
TJTravis J. Jerde
Travis J. Jerde
Prostatic inflammation is of considerable importance to urologic research because of its association with benign prostatic hyperplasia and prostate cancer. However, the mechanisms by which inflammation leads to proliferation and growth remain obscure. Here, we show that insulin-like growth factors (IGFs), previously known as critical developmental growth factors during prostate organogenesis, are induced by inflammation as part of the proliferative recovery to inflammation. Using genetic models and in vivo IGF receptor blockade, we demonstrate that the hyperplastic response to inflammation depends on interleukin-1–driven IGF signaling. We show that human prostatic hyperplasia is associated with IGF pathway activation specifically localized to foci of inflammation. This demonstrates that mechanisms of inflammation-induced epithelial proliferation and hyperplasia involve the induction of developmental growth factors, further establishing a link between inflammatory and developmental signals and providing a mechanistic basis for the management of proliferative diseases by IGF pathway modulation.